logo-loader
viewRELX PLC

RELX downgraded to ‘hold’ as Berenberg struggles to see ‘meaningful upside’ after share price surge

The bank said that they thought RELX investors should stick with their existing investments, but it was “hard to justify putting fresh money into the name at these levels”

RELX PLC - RELX downgraded to ‘hold’ as Berenberg struggles to see ‘meaningful upside’ after share price surge

RELX PLC (LON:REL) has been lowered to ‘hold’ from ‘buy’ by analysts at Berenberg as the German bank struggled to see any upside in the shares following a surge over the last 12 months.

In a Friday note, which also saw the FTSE 100 firm’s target price lowered to 2,100p from 2,120p, Berenberg’s analysts said there was now “more potential from stocks that have sold off due to coronavirus fears” and that while they thought RELX investors should stick with their existing investments, it was “hard to justify putting fresh money into the name at these levels”, with the shares having risen 18% year-on-year.

READ: RELX profits rise in 2019, chairman departs

However, the broker said it continued to view the company positively, saying its reliability in generating expansion in its business was “impressive and is broad-based across the divisions, with all delivering increased margins despite ongoing investment in new products and dilution from bolt-on acquisitions”.

They added that despite the risk of the coronavirus outbreak affecting its exhibitions business, Berenberg only expected that the firm will be “modestly affected in 2020” unless the virus became pandemic in nature.

Shares in RELX were 0.1% lower at 2,069p in mid-morning trading.

Quick facts: RELX PLC

Price: 2079 GBX

LSE:REL
Market: LSE
Market Cap: £40.21 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Faron Pharma CEO confident as he looks ahead to new Traumakine study

Faron Pharmaceuticals Oy (LON:FARN) (FIRSTNORTH:FARON) CEO Dr Markku Jalkanen caught up with Proactive London's Andrew Scott soon after announcing they've amended the protocol for a second phase III study of its drug for acute respiratory distress syndrome (ARDS). The tweak's in response to...

18 hours, 5 minutes ago

2 min read